Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCTBiotechnology
+$0.15 today
- Market cap
- $231.73M
- Beta
- 2.35
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$2.77
Volume 0.64M
Average 0.43M
ARCT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $26.96M (cash outflow) rose 91.6% year over year, ahead of the +15.4% change in trailing-twelve-month net income. Sequentially, it fell 7.3% from the prior quarter.
Context
- Net income amounted to 97.9% of revenue in FY2025, up 39.4 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 8 analysts of -$83.45M (+26.9%) for the fiscal year ending Dec 2026, a step up from the -18.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$26.96M-7.3% QoQ
- Last fiscal yearDec 2025
- -$65.78M-18.7% YoY
- LTMMar 2026
- -$78.67M+15.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +91.6% | +208.7% | +117.1 pp |
| 1 year | -18.7% | +26.9% | +45.6 pp |
| 3-year CAGR | — | +10.5% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (65.78M) USD
- Year-over-year change
- +18.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (65.78M) | +18.7% |
| FY2024 | 2024-12-31 | (80.94M) | -172.3% |
| FY2023 | 2023-12-31 | (29.73M) | -417.9% |
| FY2022 | 2022-12-31 | 9.35M | +104.6% |
| FY2021 | 2021-12-31 | (203.67M) | — |
Net Income vs competitors
How ARCT compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +15.4% is the 6th highest of 10, against a peer median of +21.5%.
- Net income amounts to 173.5% of revenue for ARCT, versus a peer median of 216.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $442.72M USD | -23.4% | — | 676.0% | |
| LTM Mar 2026 | $209.38M USD | -18.9% | +0.2% | — | |
| LTM Mar 2026 | $169.52M USD | +21.5% | +11.0% | — | |
| LTM Mar 2026 | $160.72M USD | +309.9% | -21.6% | 84.0% | |
| LTM Mar 2026 | €146.23M EUR | +81.9% | -7.0% | 93.5% | |
| LTM Mar 2026 | $145.44M USD | — | +20.7% | 15782.6% | |
| LTM Mar 2026 | $87.84M USD | -118.3% | — | 14.7% | |
| LTM Mar 2026 | $84.93M USD | -12.0% | -32.8% | — | |
| LTM Mar 2026 | $78.67M USD | +15.4% | — | 173.5% | |
| LTM Mar 2026 | €45.62M EUR | +51.2% | -14.2% | 339.4% | |
| LTM Mar 2026 | $41.54M USD | +56.8% | +27.7% | — | |
| Peer median (excluding ARCT) | — | +21.5% | -3.4% | 216.5% | |
Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (203.67M) | 9.35M | (29.73M) | (80.94M) | (65.78M) |
| Depreciation & Amortization | 1.19M | 1.53M | 2.96M | 3.54M | 3.03M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 28.92M | 30.61M | 34.65M | 37.99M | 25.41M |
| Change in Working Capital | 32.63M | (12.56M) | 7.38M | (20.81M) | (39.2M) |
| Accounts Receivables | (1.24M) | 603K | (29.3M) | 28.09M | (1.59M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (769K) | (3.11M) | (2.24M) | 1.92M | (2.96M) |
| Other Working Capital | 34.64M | (10.05M) | 38.92M | (50.81M) | (34.65M) |
| Other Non-Cash Items | 5.9M | 3.06M | (33.36M) | 471K | 2.28M |
| Operating Cash Flow | (135.04M) | 31.99M | (18.1M) | (59.75M) | (74.27M) |
| Capital Expenditures | (3.41M) | (7.73M) | (2.9M) | (648K) | (230K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (3.41M) | (7.73M) | (2.9M) | (648K) | (230K) |
| Debt Repayment | 46.6M | (5M) | (27.36M) | 0 | 0 |
| Common Stock Issued | 515K | 411K | 609K | 682K | 13.38M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 902K | 1.73M | 2.67M | 4.74M | 0 |
| Financing Cash Flow | 48.02M | (2.86M) | (24.09M) | 5.42M | 13.38M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (90.43M) | 21.41M | (45.09M) | (54.98M) | (61.12M) |
| Free Cash Flow | (138.45M) | 24.27M | (21M) | (60.4M) | (74.27M) |
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
Intrinsic Alpha fair value
Locked
Current Price
$8.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.